Carlos Bacino, MD, FACMG

Effective achondroplasia care depends on timely coordination across specialties, whether patients are managed at a dedicated multidisciplinary center or in the community.

Long-term achondroplasia care extends beyond medical treatment to supporting independence, well-being, and connection throughout the patient journey.

Response to growth-modulating therapy may evolve over several years. Structured monitoring helps clinicians assess benefit, manage expectations, and adapt treatment and orthopedic care when needed.

Investigational oral therapies are targeting the overactive FGFR3 pathway more directly, expanding the range of approaches under study for achondroplasia.

Once-weekly navepegritide provides sustained CNP exposure, with pivotal and longer-term data evaluating growth, skeletal alignment, physical function, and tolerability.

Long-term data provide insight into sustained growth, proportionality, and safety across different pediatric age groups receiving CNP analogue therapy.

Earlier intervention may offer opportunities to influence skeletal development, but treatment timing must be weighed against uncertainty, treatment burden, and the needs of individual families.

Height alone does not capture the full impact of achondroplasia. The panel discusses why health, function, proportionality, and independence are increasingly important measures of treatment success.

Beyond short stature, achondroplasia carries life-threatening risks at the skull base. The panel details why foramen magnum stenosis, hydrocephalus, and airway obstruction demand vigilant monitoring from infancy onward.

Characteristic clinical and radiographic findings can establish early suspicion for achondroplasia, while molecular and prenatal testing are helping clinicians confirm the diagnosis sooner.

Achondroplasia is driven by overactive FGFR3 signaling that disrupts normal growth plate function. The panel explains how this molecular pathway affects endochondral bone growth and provides the foundation for understanding targeted treatment.

Bacino highlights the recently approved treatment’s safety data and emphasizes the likelihood of increased adherence due to longer intervals between administration.